Patent · US Revoked

Anti-DLL3 antibody drug conjugates and methods of use

US9011854B2 · kind B2 · utility

0Cited by
46References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 22, 2014
Grant dateApr 21, 2015
Priority date
Expiry dateAug 22, 2034

Classification

  • Technology area (CPC —)General

Abstract

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.